ArticleBMC neurology2026
Prophylactic anti-seizure medication for post-traumatic seizures in Chinese PICUs: current practices and knowledge gaps.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate current practices and asses knowledge gaps in the use of prophylactic anti-seizure medication (ASM) for managing pediatric post-traumatic epilepsy (PTE) in Mainland China, with a particular focus on clinical decision-making of pediatric intensive care unit (PICU) physicians.
methodsA nationwide cross-sectional survey of 271 physicians across 30 tertiary hospital PICUs in 23 provinces was conducted between December 2023 and March 2024. The questionnaire assessed ASM utilization, treatment selection and duration, management of adverse events, and awareness of PTE risk factors. Descriptive statistics were used for data analysis.
resultsAmong the surveyed physicians, 72.7% reported prescribing prophylactic ASM, with levetiracetam (52.3%), phenobarbital (23.4%), and sodium valproate (22.3%) being the most common. The duration of treatment varied considerably: 29.4% of physicians continued prophylactic ASM up to 3 months following traumatic brain injury, whereas 22.3% of them limited the course to ≤ 7 days. Routine electroencephalogram monitoring was conducted by 78.7% of physicians. Common adverse events, including hepatotoxicity, rashes, and cognitive effects, were reported by 40.6% of the physicians. Notably, 85% of physicians continued ASM despite observing these complications. Hence, substantial knowledge gaps exist, particularly regarding the criteria for discontinuing ASM. SIGNIFICANCE: Significant variability exists in prophylactic ASM practices across PICUs in China, influenced by inconsistent adherence to guidelines, physician experience, and interdisciplinary collaborations. These findings highlight the urgent need to develop standardized protocols and conduct evidence-based training to optimize PTE prevention. Further research is warranted to device individualized ASM regimens tailored to the severity of the injury, age of the patients, and neurodevelopmental outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.